Literature DB >> 7892280

The RNA element encoded by the trans-activation-responsive region of human immunodeficiency virus type 1 is functional when displaced downstream of the start of transcription.

M J Churcher1, A D Lowe, M J Gait, J Karn.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) trans-activator protein, Tat, specifically stimulates transcription from the viral long terminal repeat. Tat binds to an RNA stem-loop structure encoded by the trans-activation response region (TAR). To test whether TAR is functional when displaced downstream of the start of transcription, we assayed a series of templates carrying duplicated TAR elements in cell-free transcription systems. When the normally positioned TAR element (TAR-1) is inactivated by mutations in either the Tat binding site or the apical loop sequence, which acts as the binding site for a cellular factor, transactivation can be rescued by a wild-type TAR element placed downstream (TAR-2). The TAR-2 element is functional even when placed > 200 nt downstream of TAR-1. TAR complementation experiments have also shown that a functional TAR element requires both an intact Tat binding site and an intact apical loop sequence. For example, if TAR-1 carries a mutation in the loop element it cannot be rescued by a TAR-2 element carrying a mutation in the Tat binding site. Substitution mutations in TAR-1 show that the 5' half of TAR also encodes an essential DNA element which is required for efficient transcription initiation. These results strongly suggest that Tat and cellular cofactors which bind TAR RNA associate with the transcription complex during its transit through TAR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7892280      PMCID: PMC42493          DOI: 10.1073/pnas.92.6.2408

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

2.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

3.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.

Authors:  M J Selby; E S Bain; P A Luciw; B M Peterlin
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

4.  HIV-1 tat trans-activation requires the loop sequence within tar.

Authors:  S Feng; E C Holland
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

Review 5.  RNA recognition by the human immunodeficiency virus Tat and Rev proteins.

Authors:  M J Gait; J Karn
Journal:  Trends Biochem Sci       Date:  1993-07       Impact factor: 13.807

6.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

Authors:  J Sodroski; C Rosen; F Wong-Staal; S Z Salahuddin; M Popovic; S Arya; R C Gallo; W A Haseltine
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  Structural arrangements of transcription control domains within the 5'-untranslated leader regions of the HIV-1 and HIV-2 promoters.

Authors:  K A Jones; P A Luciw; N Duchange
Journal:  Genes Dev       Date:  1988-09       Impact factor: 11.361

9.  In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions.

Authors:  M G Toohey; K A Jones
Journal:  Genes Dev       Date:  1989-03       Impact factor: 11.361

10.  Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus.

Authors:  J A Garcia; F K Wu; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  7 in total

1.  Spt5 cooperates with human immunodeficiency virus type 1 Tat by preventing premature RNA release at terminator sequences.

Authors:  Cyril F Bourgeois; Young Kyeung Kim; Mark J Churcher; Michelle J West; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

2.  Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex.

Authors:  N J Keen; M J Churcher; J Karn
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

3.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge.

Authors:  F Aboul-ela; J Karn; G Varani
Journal:  Nucleic Acids Res       Date:  1996-10-15       Impact factor: 16.971

5.  Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation.

Authors:  Young Kyeung Kim; Cyril F Bourgeois; Catherine Isel; Mark J Churcher; Jonathan Karn
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

6.  Human immunodeficiency virus type-1 Tat is an integral component of the activated transcription-elongation complex.

Authors:  N J Keen; M J Gait; J Karn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

7.  The cellular factor TRP-185 regulates RNA polymerase II binding to HIV-1 TAR RNA.

Authors:  F Wu-Baer; W S Lane; R B Gaynor
Journal:  EMBO J       Date:  1995-12-01       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.